Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.

MLA

Inoue, Atsushi, et al. “Antagonist of Fractalkine (CX3CL1) Delays the Initiation and Ameliorates the Progression of Lupus Nephritis in MRL/Lpr Mice.” Arthritis and Rheumatism, vol. 52, no. 5, May 2005, pp. 1522–33. EBSCOhost, https://doi.org/10.1002/art.21007.

APA

Inoue, A., Hasegawa, H., Kohno, M., Ito, M. R., Terada, M., Imai, T., Yoshie, O., Nose, M., & Fujita, S. (2005). Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis and Rheumatism, 52(5), 1522–1533. https://doi.org/10.1002/art.21007

Chicago

Inoue, Atsushi, Hitoshi Hasegawa, Masashi Kohno, Mitsuko R Ito, Miho Terada, Toshio Imai, Osamu Yoshie, Masato Nose, and Shigeru Fujita. 2005. “Antagonist of Fractalkine (CX3CL1) Delays the Initiation and Ameliorates the Progression of Lupus Nephritis in MRL/Lpr Mice.” Arthritis and Rheumatism 52 (5): 1522–33. doi:10.1002/art.21007.